Mega Genomics

Mega Genomics FCF/Debt

The Free Cash Flow to Debt Ratio of Mega Genomics (6667.HK) as of Oct 31, 2026 is -56.80 %. In the previous year, Free Cash Flow to Debt Ratio was 173.96 % — a change of -132.65% (lower).

FCF/Debt

-56.80 %

YoY

-132.65%

Last updated:

Free Cash Flow to Debt Ratio of Mega Genomics is 2025 -56.80 % . Free Cash Flow to Debt Ratio of Mega Genomics was 2024 173.96 % . It decreases by -132.65% lower compared to the previous year.

The Mega Genomics FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
98.95 CNY
Jan 1, 2020
446.45 CNY
Jan 1, 2021
263.54 CNY
Jan 1, 2022
-128.47 CNY
Jan 1, 2023
262.73 CNY
Jan 1, 2024
173.96 CNY
Jan 1, 2025
-56.80 CNY
The Mega Genomics FCF/Debt history
YEARFCF/DebtYoY
-56.80 %-132.65%
173.96 %-33.79%
262.73 %-304.51%
-128.47 %-148.75%
263.54 %-40.97%
446.45 %+351.21%
98.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd. generates revenue through three business segments. The Consumer Genetic Testing Services segment offers nutrition and metabolism testing, cancer risk assessment, chronic disease susceptibility analysis, pharmacogenetic testing, and infectious disease testing to individual consumers. The Cancer Screening Services segment provides specific tests including Septin9 for colorectal cancer, Syndecan-2 (SDC2) for colorectal cancer, and ring finger protein 180 (RNF180)/Septin9 for gastric cancer screening. The Other Services segment delivers genetic research and analysis services to third-party research institutions, creating additional revenue streams from institutional partnerships. The primary buyers for Consumer Genetic Testing Services are individual consumers seeking personalized health insights. Cancer Screening Services are utilized by healthcare providers and patients for early detection of colorectal and gastric cancers. Third-party research institutions purchase genetic research and analysis services from the Other Services segment to support their scientific studies and development projects. Mega Genomics Ltd. serves distinct market segments: individual consumers for genetic testing, healthcare providers for cancer screening, and research institutions for specialized genetic analysis. The company's revenue model relies on direct consumer sales, healthcare provider contracts, and institutional research partnerships to sustain its operations and growth. Mega Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mega Genomics stock

Free Cash Flow to Debt Ratio of Mega Genomics is -56.80 % in 2025.

Free Cash Flow to Debt Ratio of Mega Genomics changed from 173.96 % to -56.80 %, representing a -132.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Mega Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Mega Genomics

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Mega Genomics